Surfacide, a UV-C disinfection technology provider, has announced SURFrx, a new evidence-based, UV-C low-level disinfection programme that can achieve up to a 6-log reduction against many of the organisms commonly found on surfaces and in the air in pharmacy sterile compounding rooms.
The SURFrx programme was designed specifically for pharmacy "cleanrooms" as they prepare for the regulatory changes that go into effect for USP 797 and 800 in November of this year.
The programme includes utilisation reports and analytics including pharmaceutical consulting by Surfacide industry experts
With drug-resistant bacteria, viruses and fungi on the rise, even cleanrooms are discovering they need new ways to eradicate organisms. The SURFrx programme is a flexible monthly membership subscription that enhances existing cleaning protocols by integrating chemical-free UV-C disinfection technology for both surface and air.
The programme allows for quick and easy implementation, so there is no need to wait on capital approval to get it up and running immediately.
The programme includes:
- Custom evaluation and strategy with dedicated implementation specialist
- Surfacide (registered trademark) Helios UV-C robot
- UV-C air disinfection system
- Utilisation reports and analytics including pharmaceutical consulting by Surfacide industry experts
- Onsite training and ongoing support
"We're proud to introduce SURFrx as the wave of the future in sterile compounding room disinfection," said Gunner Lyslo, CEO & Founder of Surfacide. "Pharmacy directors are committed to patient safety and are seeking solutions that will allow them to meet the new and far more stringent requirements of the USP standard. As a leading UV-C disinfection solution for more than a decade in more than 600 healthcare facilities worldwide, we are excited to expand our technology to reach pharmaceutical settings as well."
